We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
To save content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about saving content to .
To save content items to your Kindle, first ensure no-reply@cambridge.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
Misinformation and suspicion surrounding sexually transmitted HPV – along with the social implications of administering shots to young girls – significantly hinder worldwide uptake of the vaccine. The 2006 U.S. rollout hit a quagmire of public ignorance, suspicion and paranoia, and by 2020, just 61 percent of eligible U.S. girls had been vaccinated. In Japan, anti-vax sentiment led to an HPV vaccine ban, and in Denmark, the vaccine met similar resistance. Nearly twenty years after its introduction in higher-income countries, the vaccine is vastly behind its prevention potential; in lower-income countries, its trajectory has been abysmal. Hang-ups about sexually transmitted infections and baseless fears about the vaccine have made advocating its use a cause laden with stigma. In male-dominated cultures – and in the absence of an existing delivery system – a girls-only vaccine is often stopped before it can start. And yet, without a worldwide commitment to countering misunderstanding through trust-building, hundreds of thousands of women will miss their critical opportunity to beat this disease.
The potency of a vaccine against cancer-causing HPV – and the body’s ability to clear it – offers many women a fighting chance. But extinguishing this source of cervical cancer overlooks another sexually transmitted virus that’s been raging around the globe for decades: the human immunodeficiency virus (HIV). The lethal effects of HPV mixed with HIV can be like setting gasoline on fire. HPV infections in HIV-positive women last longer, progress more quickly, recur more frequently, and are harder to eradicate. Cervical cancer in HIV-positive women – many of them in lower-income countries – strikes younger, is more aggressive, and harder to cure. Women with HIV are six times more likely to die of cervical cancer. They face a particular threat in Africa, home to two-thirds of the world’s 40 million HIV cases. Without a concerted effort to overcome the dual stigma of HIV and HPV through education, appropriate medical care to all persons with cervixes, and a means to address the vulnerability of the continent’s child brides, Africa will remain at the core of the HIV-HPV inferno – undermining the quest for global cervical cancer elimination.
Recommend this
Email your librarian or administrator to recommend adding this to your organisation's collection.